Cargando…

Kappa free light chain and neurofilament light independently predict early multiple sclerosis disease activity—a cohort study

BACKGROUND: Inter-individual courses of multiple sclerosis (MS) are extremely variable. The objective of this study was to investigate whether κ-free light chain (κ-FLC) index and serum neurofilament light (sNfL) have an additive predictive value for MS disease activity. METHODS: Patients with early...

Descripción completa

Detalles Bibliográficos
Autores principales: Hegen, Harald, Berek, Klaus, Bsteh, Gabriel, Auer, Michael, Altmann, Patrick, Di Pauli, Franziska, Grams, Astrid, Milosavljevic, Dejan, Ponleitner, Markus, Poskaite, Paulina, Schnabl, Christine, Wurth, Sebastian, Zinganell, Anne, Berger, Thomas, Walde, Janette, Deisenhammer, Florian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10148088/
https://www.ncbi.nlm.nih.gov/pubmed/37086651
http://dx.doi.org/10.1016/j.ebiom.2023.104573
_version_ 1785034923711660032
author Hegen, Harald
Berek, Klaus
Bsteh, Gabriel
Auer, Michael
Altmann, Patrick
Di Pauli, Franziska
Grams, Astrid
Milosavljevic, Dejan
Ponleitner, Markus
Poskaite, Paulina
Schnabl, Christine
Wurth, Sebastian
Zinganell, Anne
Berger, Thomas
Walde, Janette
Deisenhammer, Florian
author_facet Hegen, Harald
Berek, Klaus
Bsteh, Gabriel
Auer, Michael
Altmann, Patrick
Di Pauli, Franziska
Grams, Astrid
Milosavljevic, Dejan
Ponleitner, Markus
Poskaite, Paulina
Schnabl, Christine
Wurth, Sebastian
Zinganell, Anne
Berger, Thomas
Walde, Janette
Deisenhammer, Florian
author_sort Hegen, Harald
collection PubMed
description BACKGROUND: Inter-individual courses of multiple sclerosis (MS) are extremely variable. The objective of this study was to investigate whether κ-free light chain (κ-FLC) index and serum neurofilament light (sNfL) have an additive predictive value for MS disease activity. METHODS: Patients with early MS who had cerebrospinal fluid (CSF) and serum sampling at disease onset were followed for four years. At baseline, age, sex, disease duration, number of T2-hyperintense (T2L), and contrast-enhancing T1 lesions (CEL) on MRI were determined. During follow-up, the occurrence of a second clinical attack and start of disease-modifying treatment (DMT) were registered. κ-FLC was measured by nephelometry, and κ-FLC index calculated as [CSF κ-FLC/serum κ-FLC]/albumin quotient. sNfL was determined by single-molecule array, and age- and body-mass-index adjusted Z scores were calculated. FINDINGS: A total of 86 patients at a mean age of 33 ± 10 years and with a female predominance of 67% were included; 36 (42%) patients experienced a second clinical attack during follow-up. Cox regression analysis adjusted for age, sex, T2L, CEL, disease and follow-up duration, and DMT use during follow-up revealed that both κ-FLC index as well as sNfL Z score independently predict time to second clinical attack. The chance for freedom of relapse within 12 months was 2% in patients with high levels of κ-FLC index (>100) and high sNfL Z score (>3), 30% in patients with high κ-FLC index (>100) and lower sNfL Z score (≤3), 70% in patients with lower κ-FLC index (≤100) but high sNfL Z score (>3), and 90% in patients with lower levels of κ-FLC index (≤100) and sNfL Z score (≤3). INTERPRETATION: κ-FLC index and sNfL Z score have an additive predictive value for early MS disease activity that is independent of known predictors. FUNDING: This study was funded by a grant of the charitable foundation of the Austrian Multiple Sclerosis Society.
format Online
Article
Text
id pubmed-10148088
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-101480882023-04-30 Kappa free light chain and neurofilament light independently predict early multiple sclerosis disease activity—a cohort study Hegen, Harald Berek, Klaus Bsteh, Gabriel Auer, Michael Altmann, Patrick Di Pauli, Franziska Grams, Astrid Milosavljevic, Dejan Ponleitner, Markus Poskaite, Paulina Schnabl, Christine Wurth, Sebastian Zinganell, Anne Berger, Thomas Walde, Janette Deisenhammer, Florian eBioMedicine Articles BACKGROUND: Inter-individual courses of multiple sclerosis (MS) are extremely variable. The objective of this study was to investigate whether κ-free light chain (κ-FLC) index and serum neurofilament light (sNfL) have an additive predictive value for MS disease activity. METHODS: Patients with early MS who had cerebrospinal fluid (CSF) and serum sampling at disease onset were followed for four years. At baseline, age, sex, disease duration, number of T2-hyperintense (T2L), and contrast-enhancing T1 lesions (CEL) on MRI were determined. During follow-up, the occurrence of a second clinical attack and start of disease-modifying treatment (DMT) were registered. κ-FLC was measured by nephelometry, and κ-FLC index calculated as [CSF κ-FLC/serum κ-FLC]/albumin quotient. sNfL was determined by single-molecule array, and age- and body-mass-index adjusted Z scores were calculated. FINDINGS: A total of 86 patients at a mean age of 33 ± 10 years and with a female predominance of 67% were included; 36 (42%) patients experienced a second clinical attack during follow-up. Cox regression analysis adjusted for age, sex, T2L, CEL, disease and follow-up duration, and DMT use during follow-up revealed that both κ-FLC index as well as sNfL Z score independently predict time to second clinical attack. The chance for freedom of relapse within 12 months was 2% in patients with high levels of κ-FLC index (>100) and high sNfL Z score (>3), 30% in patients with high κ-FLC index (>100) and lower sNfL Z score (≤3), 70% in patients with lower κ-FLC index (≤100) but high sNfL Z score (>3), and 90% in patients with lower levels of κ-FLC index (≤100) and sNfL Z score (≤3). INTERPRETATION: κ-FLC index and sNfL Z score have an additive predictive value for early MS disease activity that is independent of known predictors. FUNDING: This study was funded by a grant of the charitable foundation of the Austrian Multiple Sclerosis Society. Elsevier 2023-04-20 /pmc/articles/PMC10148088/ /pubmed/37086651 http://dx.doi.org/10.1016/j.ebiom.2023.104573 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Articles
Hegen, Harald
Berek, Klaus
Bsteh, Gabriel
Auer, Michael
Altmann, Patrick
Di Pauli, Franziska
Grams, Astrid
Milosavljevic, Dejan
Ponleitner, Markus
Poskaite, Paulina
Schnabl, Christine
Wurth, Sebastian
Zinganell, Anne
Berger, Thomas
Walde, Janette
Deisenhammer, Florian
Kappa free light chain and neurofilament light independently predict early multiple sclerosis disease activity—a cohort study
title Kappa free light chain and neurofilament light independently predict early multiple sclerosis disease activity—a cohort study
title_full Kappa free light chain and neurofilament light independently predict early multiple sclerosis disease activity—a cohort study
title_fullStr Kappa free light chain and neurofilament light independently predict early multiple sclerosis disease activity—a cohort study
title_full_unstemmed Kappa free light chain and neurofilament light independently predict early multiple sclerosis disease activity—a cohort study
title_short Kappa free light chain and neurofilament light independently predict early multiple sclerosis disease activity—a cohort study
title_sort kappa free light chain and neurofilament light independently predict early multiple sclerosis disease activity—a cohort study
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10148088/
https://www.ncbi.nlm.nih.gov/pubmed/37086651
http://dx.doi.org/10.1016/j.ebiom.2023.104573
work_keys_str_mv AT hegenharald kappafreelightchainandneurofilamentlightindependentlypredictearlymultiplesclerosisdiseaseactivityacohortstudy
AT berekklaus kappafreelightchainandneurofilamentlightindependentlypredictearlymultiplesclerosisdiseaseactivityacohortstudy
AT bstehgabriel kappafreelightchainandneurofilamentlightindependentlypredictearlymultiplesclerosisdiseaseactivityacohortstudy
AT auermichael kappafreelightchainandneurofilamentlightindependentlypredictearlymultiplesclerosisdiseaseactivityacohortstudy
AT altmannpatrick kappafreelightchainandneurofilamentlightindependentlypredictearlymultiplesclerosisdiseaseactivityacohortstudy
AT dipaulifranziska kappafreelightchainandneurofilamentlightindependentlypredictearlymultiplesclerosisdiseaseactivityacohortstudy
AT gramsastrid kappafreelightchainandneurofilamentlightindependentlypredictearlymultiplesclerosisdiseaseactivityacohortstudy
AT milosavljevicdejan kappafreelightchainandneurofilamentlightindependentlypredictearlymultiplesclerosisdiseaseactivityacohortstudy
AT ponleitnermarkus kappafreelightchainandneurofilamentlightindependentlypredictearlymultiplesclerosisdiseaseactivityacohortstudy
AT poskaitepaulina kappafreelightchainandneurofilamentlightindependentlypredictearlymultiplesclerosisdiseaseactivityacohortstudy
AT schnablchristine kappafreelightchainandneurofilamentlightindependentlypredictearlymultiplesclerosisdiseaseactivityacohortstudy
AT wurthsebastian kappafreelightchainandneurofilamentlightindependentlypredictearlymultiplesclerosisdiseaseactivityacohortstudy
AT zinganellanne kappafreelightchainandneurofilamentlightindependentlypredictearlymultiplesclerosisdiseaseactivityacohortstudy
AT bergerthomas kappafreelightchainandneurofilamentlightindependentlypredictearlymultiplesclerosisdiseaseactivityacohortstudy
AT waldejanette kappafreelightchainandneurofilamentlightindependentlypredictearlymultiplesclerosisdiseaseactivityacohortstudy
AT deisenhammerflorian kappafreelightchainandneurofilamentlightindependentlypredictearlymultiplesclerosisdiseaseactivityacohortstudy